# Indapta Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/indapta-therapeutics

- Industry: Biotechnology
- Headquarters: Houston, US
- Website: www.indapta.com
- Total disclosed funding: $34M
- Latest round: Series A (Jan 28, 2022)
- Investors on record: 5

## About

Founded in 2017, and based in Texas, US, Indapta Therapeutics Inc. operates as a biotechnology company that offers cell therapy to treat multiple types of cancer. The company was founded by its Chairman Ronald Martell, and Chief Strategy Officer Guy Dipierro. In February 2022, Indapta Therapeutics Inc. raised USD 50 million in series A funding co-led by new investors Leaps by Bayer, RA Capital, and Vertex Ventures US. As of 2022, the company is led by its CEO Mark W. Frohlich. In December 2024, Indapta Therapeutics Inc. raised USD 22.5 million in venture funding from returning investors Leaps by Bayer, Myeloma Investment Fund, Pontifax Venture Capital, RA Capital Management, and Vertex Ventures.


Indapta Therapeutics creates and sells patented allogeneic cell therapy for the treatment of a variety of hematologic cancers and solid tumor malignancies. The company’s therapy involves building immunotherapy using G-NK cells, which are FcR?-deficient natural killer cells that aid the immune system of cancer patients in targeting and destroying tumor cells. As of 2022, Indapta plans to utilize its G-NK cell treatment in combination with a number of FDA-approved antibodies to treat tumors.

The company plans to use the February funding to advance the development of G-NK cell therapy to treat multiple types of cancer.

## Funding rounds

- Series A, Jan 28, 2022, $34M — Lonza Group Ltd., RA Capital Management, Vertex Ventures, Leaps by Bayer, Myeloma Investment Fund

## Investors

- Lonza Group Ltd. — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Vertex Ventures (https://capitalatlas.ai/funds/vertex-ventures) — Series A
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A
- Myeloma Investment Fund (https://capitalatlas.ai/funds/myeloma-investment-fund) — Series A